Canadian diagnostics firm MedMira has obtained the CE mark for its Vyra COVID-19 Antigen Test.
The test has been designed to detect the SARS-CoV-2 virus in the swab samples.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
MedMira has developed the rapid antigen test using its patented Rapid Vertical Flow (RVF) technology.
This test expands the current Covid-19 product family and addresses the need for a quick, reliable, and easy-to-use testing solution.
The test is designed to be non-invasive and user-friendly to make it more suitable for any settings.
The Vyra COVID-19 Antigen Test is currently available in Europe as well as in countries that accept the CE mark.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMedMira CEO Hermes Chan said: “Whereas VYRA COVID-19 provides a high-quality single antigen test for the detection of SARS-CoV-2 designed for customers who are worried about a Covid-19 infection, our upcoming VYRA CoV2Flu Antigen Test will further complement our product offering to customers who wish to have a result for Covid-19 or Flu A or Flu B immediately.
“With the increasing infection rates during the next few months and the need for quality rapid testing solutions, MedMira’s VYRA Covid-19 is the fastest and most reliable answer.”
In the coming weeks, the diagnostics company expects to receive a CE mark for the REVEALCOVID-19 Nab-Y Neutralising Antibody Test and VYRA CoV2Flu.
Upon receipt of the CE mark, MedMira will be able to provide a complete set of Covid-19 related products to its distribution partners.
In February, the company received the CE mark for its REVEALCOVID-19 PLUS Total Antibody Test, which has been designed to identify the presence of total antibodies.
